Teenage mutant neutrophilic precursors: Leukemia cutis with IDH2 mutation on enasidenib therapy

被引：4
|
作者：
Kallen, Michael E. [1 ]
Koka, Rima [1 ]
Singh, Zeba [1 ]
Sanchez-Petitto, Gabriela [2 ]
Zaman, Qamar U. [3 ]
Yared, Jean A. [2 ]
Duong, Vu H. [2 ]
机构：
[1] Univ Maryland, Sch Med, Dept Pathol, 22 S Greene St,NBW-54, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Med, Div Hematol Oncol, Baltimore, MD 21201 USA
[3] Univ Pittsburgh, Med Ctr, Western Maryland, Cumberland, MD USA
来源：
LEUKEMIA RESEARCH | 2020年 / 96卷
关键词：
DIFFERENTIATION SYNDROME;
D O I：
10.1016/j.leukres.2020.106406
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
    Stein, Eytan M.
    DiNardo, Courtney D.
    Pollyea, Daniel A.
    Fathi, Amir T.
    Roboz, Gail J.
    Altman, Jessica K.
    Stone, Richard M.
    DeAngelo, Daniel J.
    Levine, Ross L.
    Flinn, Ian W.
    Kantarjian, Hagop M.
    Collins, Robert
    Patel, Manish R.
    Frankel, Arthur E.
    Stein, Anthony
    Sekeres, Mikkael A.
    Swords, Ronan T.
    Medeiros, Bruno C.
    Willekens, Christophe
    Vyas, Paresh
    Tosolini, Alessandra
    Xu, Qiang
    Knight, Robert D.
    Yen, Katharine E.
    Agresta, Sam
    de Botton, Stephane
    Tallman, Martin S.
    BLOOD, 2017, 130 (06) : 722 - 731
  • [2] The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia
    Abou Dalle, Iman
    DiNardo, Courtney D.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2018, 9 (07) : 163 - 173
  • [3] Enasidenib for Patients With Relapsed Acute Myeloid Leukemia and the IDH2 Mutation
    DiNardo, Courtney
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (04) : 247 - 249
  • [4] Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome
    DiNardo, Courtney D.
    Venugopal, Sangeetha
    Lachowiez, Curtis
    Takahashi, Koichi
    Loghavi, Sanam
    Montalban-Bravo, Guillermo
    Wang, Xuemei
    Carraway, Hetty
    Sekeres, Mikkael
    Sukkur, Ameenah
    Hammond, Danielle
    Chien, Kelly
    Maiti, Abhishek
    Masarova, Lucia
    Sasaki, Koji
    Alvarado, Yesid
    Kadia, Tapan
    Short, Nicholas J.
    Daver, Naval
    Borthakur, Gautam
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Patel, Bhumika
    Dezern, Amy
    Roboz, Gail
    Garcia-Manero, Guillermo
    BLOOD ADVANCES, 2023, 7 (11) : 2378 - 2387
  • [5] Enasidenib in relapsed aggressive systemic mastocytosis with IDH2 mutation
    Del Rio Verduzco, Alejandro
    Al Darobi, Ali
    Heimbigner, Alex
    Heers, Hayley
    Ulrickson, Matthew
    LEUKEMIA & LYMPHOMA, 2025, 66 (01) : 170 - 173
  • [6] Enasidenib Drives Maturation of Human Erythroid Precursors Independently of IDH2
    Dutta, Ritika
    Zhang, Tian Y.
    Koehnke, Thomas
    Thomas, Daniel
    Gars, Eric
    Stafford, Melissa
    Nakauchi, Yusuke
    Kaur, Satinder
    Yin, Raymond
    Narla, Anupama
    Majeti, Ravindra
    BLOOD, 2019, 134
  • [7] Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
    Dogra, Raghav
    Bhatia, Rohit
    Shankar, Ravi
    Bansal, Parveen
    Rawal, Ravindra K.
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2018, 18 (14) : 1936 - 1951
  • [8] Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia
    Stein, Eytan M.
    FUTURE ONCOLOGY, 2018, 14 (01) : 23 - 40
  • [9] Enasidenib, an Oral Therapy in Mutant IDH2 Relapsed/Refractory Acute Myeloid Leukemia: A Real-Life Single Center Experience
    Riva, Marta
    Rizzo, Lorenzo
    Mancini, Valentina
    Greco, Rosa
    Bertani, Giambattista
    Zucchetti, Elisa
    Diral, Elisa
    Nichelatti, Michele
    Veronese, Silvio Marco
    Grillo, Giovanni
    Cairoli, Roberto
    BLOOD, 2020, 136
  • [10] Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib
    Quek, Lynn
    David, Muriel D.
    Kennedy, Alison
    Metzner, Marlen
    Amatangelo, Michael
    Shih, Alan
    Stoilova, Bilyana
    Quivoron, Cyril
    Heiblig, Mael
    Willekens, Christophe
    Saada, Veronique
    Alsafadi, Samar
    Vijayabaskar, M. S.
    Peniket, Andy
    Bernard, Oliver A.
    Agresta, Sam
    Yen, Katharine
    MacBeth, Kyle
    Stein, Eytan
    Vassiliou, George S.
    Levine, Ross
    De Botton, Stephane
    Thakurte, Anjan
    Penard-Lacronique, Virginie
    Vyas, Paresh
    NATURE MEDICINE, 2018, 24 (08) : 1167 - +
12345